Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDAC open hearing

This article was originally published in The Tan Sheet

Executive Summary

Those wishing to speak during public comment section of Sept. 19-20 NDAC meeting on acetaminophen, NSAID, aspirin safety must submit their final statements to FDA by Sept. 4, along with full disclosure on potential conflicts of interest. Submissions should be labeled either "Open APAP," "Open NSAIDs" or "Open ASA," FDA advises, noting "we think separate submissions" on each type of analgesic "would be desirable, but you can use your own judgement." All statements will be posted on 1FDA's Web site before the meeting, agency adds...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS094418

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel